Table 4 Analysis of the risk factors of neonatal hypoglycemia in the RD intravenous administration group
No Neonatal Hypoglycemia | Neonatal Hypoglycemia | P value | AOR | 95%CI | P value | |
|---|---|---|---|---|---|---|
Cases (n) | 36 (38.3) | 58 (61.7) | ||||
Maternal age over 35 (n) | 7 (19.4) | 24 (41.4) | 0.042 | 3.385 | 1.082–10.588 | 0.036 |
Maternal height (cm) | 158.5 (140.0 – 169.0) | 158.0 (146.0 – 174.0) | 0.703 | |||
Pre-pregnancy BMI (kg/m2) | 20.4 (15.3 – 26.6) | 20.3 (17.0 – 33.8) | 0.876 | |||
Maternal weight gain (kg) | 8.0 (1.5 – 18.0) | 9.0 (3.0 – 17.5) | 0.117 | |||
Gestational age (wk/day) | 37 /1 (36/0 – 38/4) | 37/0 (36/0 – 37/6) | 0.598 | |||
Birth weight < 2500 g (n) | 7 (19.4) | 26 (44.8) | 0.015 | 2.479 | 0.774–7.942 | 0.126 |
Twin birth (n) | 6 (16.7) | 25 (43.1) | 0.012 | 2.417 | 0.743–7.863 | 0.143 |
Administration of magnesium sulfate (n) | 4 (11.1) | 11 (19.0) | 0.393 | |||
Administration length (day) | 43.5 (0.04 – 134.0) | 38.5 (6.0 – 147.0) | 0.694 | |||
Final administration dose rate (μg/min) | 65.0 (33.0 – 192.3) | 93.3 (32.1 – 192.3) | 0.048 | 0.999 | 0.987–1.011 | 0.878 |
Interval (hr) | 12.5 (0.0 – 154.0) | 1.3 (0.0 – 167.9) | < 0.001 | 0.974 | 0.953–0.996 | 0.020 |